Zacks Investment Research downgraded shares of USANA Health Sciences (NYSE:USNA) from a hold rating to a sell rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “USANA Health Sciences Inc. develops and manufactures high-quality nutritional, personal care and weight management products. The company’s three primary product lines consist of nutritional, personal care and weight management products. The company’s products are distributed primarily through a network marketing system. “

A number of other analysts have also recently issued reports on USNA. StockNews.com cut USANA Health Sciences from a strong-buy rating to a buy rating in a research report on Friday, February 11th. TheStreet lowered USANA Health Sciences from a b rating to a c+ rating in a research note on Wednesday, February 9th.

Shares of NYSE USNA opened at $88.76 on Tuesday. The business’s 50 day moving average is $97.92 and its two-hundred day moving average is $97.29. The company has a market cap of $1.73 billion, a P/E ratio of 13.55 and a beta of 0.85. USANA Health Sciences has a 12 month low of $79.92 and a 12 month high of $107.85.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Monday, February 7th. The company reported $1.03 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.28 by ($0.25). USANA Health Sciences had a return on equity of 32.68% and a net margin of 11.05%. During the same period in the prior year, the company earned $1.87 earnings per share. Sell-side analysts expect that USANA Health Sciences will post 5.98 earnings per share for the current year.

In other USANA Health Sciences news, insider Daniel A. Macuga sold 368 shares of the firm’s stock in a transaction on Wednesday, December 8th. The stock was sold at an average price of $100.86, for a total transaction of $37,116.48. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gilbert A. Fuller sold 312 shares of USANA Health Sciences stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $89.62, for a total value of $27,961.44. The disclosure for this sale can be found here. Insiders have sold 9,911 shares of company stock valued at $974,137 over the last ninety days. 0.21% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the company. Reilly Financial Advisors LLC acquired a new position in shares of USANA Health Sciences in the 4th quarter valued at about $32,000. Covestor Ltd purchased a new position in shares of USANA Health Sciences in the 4th quarter worth approximately $49,000. Point72 Hong Kong Ltd lifted its stake in USANA Health Sciences by 488.0% in the third quarter. Point72 Hong Kong Ltd now owns 488 shares of the company’s stock valued at $45,000 after purchasing an additional 405 shares during the last quarter. Altshuler Shaham Ltd lifted its position in shares of USANA Health Sciences by 28.3% during the third quarter. Altshuler Shaham Ltd now owns 508 shares of the company’s stock worth $47,000 after acquiring an additional 112 shares in the last quarter. Finally, CWM LLC purchased a new stake in shares of USANA Health Sciences during the fourth quarter worth $71,000. 54.82% of the stock is currently owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.

Read More

Get a free copy of the Zacks research report on USANA Health Sciences (USNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com